This manifests as cramping, bloating, or vague upper abdominal fullness
People who are pregnant, breastfeeding, or managing a dermatological condition should seek professional advice before starting either product
Mechanisms Research demonstrates: Clinical Applications Evidence supports its use for: In longevity programs, BPC-157 is valued for systemic repair and anti-inflammatory effects
OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
As neurons shrink, oxidative stress rises, and synaptic density fades, memory, focus, and resilience begin to erode